CA2859940C - Method for administration of an anti tumor agent - Google Patents

Method for administration of an anti tumor agent Download PDF

Info

Publication number
CA2859940C
CA2859940C CA2859940A CA2859940A CA2859940C CA 2859940 C CA2859940 C CA 2859940C CA 2859940 A CA2859940 A CA 2859940A CA 2859940 A CA2859940 A CA 2859940A CA 2859940 C CA2859940 C CA 2859940C
Authority
CA
Canada
Prior art keywords
day
days
compound
administration
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2859940A
Other languages
English (en)
French (fr)
Other versions
CA2859940A1 (en
Inventor
Kelli Glenn
Brian Higgins
Gwen Nichols
Kathryn E. Packman
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2859940A1 publication Critical patent/CA2859940A1/en
Application granted granted Critical
Publication of CA2859940C publication Critical patent/CA2859940C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2859940A 2012-03-19 2013-03-15 Method for administration of an anti tumor agent Active CA2859940C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612429P 2012-03-19 2012-03-19
US61/612,429 2012-03-19
PCT/EP2013/055324 WO2013139687A1 (en) 2012-03-19 2013-03-15 Method for administration of an anti tumor agent

Publications (2)

Publication Number Publication Date
CA2859940A1 CA2859940A1 (en) 2013-09-26
CA2859940C true CA2859940C (en) 2020-03-24

Family

ID=47913395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859940A Active CA2859940C (en) 2012-03-19 2013-03-15 Method for administration of an anti tumor agent

Country Status (21)

Country Link
US (4) US20130245089A1 (https=)
EP (1) EP2827858B1 (https=)
JP (2) JP6224690B2 (https=)
KR (4) KR102438597B1 (https=)
CN (2) CN104203232A (https=)
BR (1) BR112014018135A8 (https=)
CA (1) CA2859940C (https=)
CY (1) CY1118070T1 (https=)
DK (1) DK2827858T3 (https=)
ES (1) ES2593066T3 (https=)
HK (1) HK1204934A1 (https=)
HR (1) HRP20161295T1 (https=)
HU (1) HUE029933T2 (https=)
LT (1) LT2827858T (https=)
MX (1) MX356948B (https=)
PL (1) PL2827858T3 (https=)
PT (1) PT2827858T (https=)
RS (1) RS55250B1 (https=)
RU (1) RU2638795C2 (https=)
SI (1) SI2827858T1 (https=)
WO (1) WO2013139687A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112353762A (zh) * 2013-01-22 2021-02-12 霍夫曼-拉罗奇有限公司 具有改善的生物利用度的药物组合物
EP3459933B1 (en) 2014-04-15 2022-08-24 F. Hoffmann-La Roche AG Solid forms of a pharmaceutically active compound
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
MX388093B (es) 2016-11-15 2025-03-19 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.
US20210122831A1 (en) 2017-03-27 2021-04-29 Noile-Immune Biotech, Inc. Chimeric antigen receptor
CA3052543A1 (en) 2017-03-31 2018-10-04 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
TWI791794B (zh) 2018-03-20 2023-02-11 瑞士商諾華公司 藥物組合
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595107A (zh) * 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Also Published As

Publication number Publication date
CY1118070T1 (el) 2017-06-28
ES2593066T3 (es) 2016-12-05
EP2827858A1 (en) 2015-01-28
JP6224690B2 (ja) 2017-11-01
EP2827858B1 (en) 2016-07-20
BR112014018135A2 (https=) 2017-06-20
KR20210016073A (ko) 2021-02-10
KR102438597B1 (ko) 2022-08-31
US20190328708A1 (en) 2019-10-31
PT2827858T (pt) 2016-09-23
MX2014010586A (es) 2014-09-18
DK2827858T3 (en) 2016-08-22
JP2015510906A (ja) 2015-04-13
HRP20161295T1 (hr) 2016-11-18
US11738003B2 (en) 2023-08-29
CN104203232A (zh) 2014-12-10
BR112014018135A8 (pt) 2021-10-19
HK1204934A1 (en) 2015-12-11
HUE029933T2 (en) 2017-04-28
WO2013139687A1 (en) 2013-09-26
KR20190035957A (ko) 2019-04-03
JP2017061461A (ja) 2017-03-30
PL2827858T3 (pl) 2017-01-31
RU2638795C2 (ru) 2017-12-15
LT2827858T (lt) 2016-10-10
CN110013478A (zh) 2019-07-16
KR20140133583A (ko) 2014-11-19
RS55250B1 (sr) 2017-02-28
RU2014141365A (ru) 2016-05-10
MX356948B (es) 2018-06-20
KR20160089549A (ko) 2016-07-27
US20210069149A1 (en) 2021-03-11
SI2827858T1 (sl) 2016-11-30
US20150126575A1 (en) 2015-05-07
US20130245089A1 (en) 2013-09-19
CA2859940A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
CA2859940C (en) Method for administration of an anti tumor agent
US20250082931A1 (en) Treating Gastric Cancer Using TTFields Combined with XELOX, FOLFOX or the Individual Constituents Thereof
CA2785822C (en) Methods of providing weight loss therapy in patients with major depression
CN107714684A (zh) 包含α‑甲基‑DL‑酪氨酸的药物组合物及其应用
JP2024516795A (ja) エベロリムスおよびアムセネストラントを含む組合せ物
JP2019501184A (ja) 鉄化合物及びシトレート化合物を用いる併用療法
Abbasi et al. Allopurinol mouthwash for prevention or alleviation radiotherapy induced oral mucositis: a randomized, placebo-controlled trial
ALTINDAĞ et al. Intoxication due to high dose methotrexate in a patient with rheumatoid arthritis: a case report
US11382892B2 (en) Method for administration
HK40011479A (en) Method for administration of an anti-tumor agent
JP2013510126A (ja) コリン含有医薬組成物
SCHNEIDER File Claims by Oct. for UnitedHealth Settlement
Schneider ‘Red Flags’ Rule Delayed Through End of 2010
KüçükoĞlu Intoxication Due to High Dose Methotrexate in a Patient with Rheumatoid Arthritis: A Case Report.
Hörmann Caphosol Mundspülung zur Therapie der Chemotherapie-induzierten oralen Mukositis: eine retrospektive Kohortenstudie
Mukohara et al. 421 POSTER Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180226

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250924

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260226